^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PIK3CA H1047X

    i
    Other names: PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, Phosphoinositide-3-kinase, catalytic, alpha polypeptide, Serine/threonine protein kinase PIK3CA, PtdIns-3-kinase subunit P110-alpha, PI3K-alpha, Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 KDa catalytic subunit alpha, Phosphatidylinositol 3-kinase, Catalytic, 110-KD, alpha, PI3-kinase P110 subunit alpha, PI3-kinase subunit alpha, PtdIns-3-kinase subunit alpha, PI3Kalpha, P110alpha, PI3K
    Entrez ID:
    5290
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    over1year
    Characteristics of PIK3CA gene mutations in Her2-low breast cancer (PubMed, Arkh Patol)
    Statistically significant increase in the frequency of exon 9 mutations of the PIK3CA gene is specific for the group of patients with Her2-low BC. Our results supported the concept of Her2-low BCs as the unique entity and pointed out the need of their further study.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    HER-2 positive • HER-2 negative • PIK3CA mutation • HER-2 mutation • HER-2 expression • HER-2 underexpression • PIK3CA E545 • PIK3CA E542 • PIK3CA E545X • PIK3CA H1047X
    |
    cobas® PIK3CA Mutation Test
    |
    Piqray (alpelisib)
    almost3years
    Discovery and characterization of a mutant selective PI3KαH1047Xinhibitor with a best-in-class profile (AACR 2022)
    Alpelisib is a PI3Kα isoform-selective, orthosteric kinase inhibitor, having equivalent activity on wild-type (wt) and mutant (mt) forms and was approved to treat PI3Kα mt, HR+/HER2- breast cancer in combination with fulvestrant, nearly doubling progression-free survival (Andre 2019)...ST-814 has robust anti-tumor activity in PI3KαH1047X in xenografts, with efficacy similar or superior to alpelisib dosed at 50 mg/kg (Table 1)...A clinical candidate from this program is currently in IND enabling studies. >
    Late-breaking abstract
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    HER-2 negative • PIK3CA mutation • PIK3CA H1047R • PIK3CA E545 • PIK3CA H1047 • PIK3CA E542 • PIK3CA H1047X
    |
    Piqray (alpelisib) • fulvestrant • STX-478
    almost3years
    Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer (clinicaltrials.gov)
    P2, N=11, Completed, NRG Oncology | Active, not recruiting --> Completed
    Trial completion
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    PIK3CA mutation • PIK3CA H1047R • PIK3CA E545K • PIK3CA E545 • PIK3CA E542 • PIK3CA H1047L • PIK3CA M1043I • PIK3CA C420R • PIK3CA E545A • PIK3CA N345K • PIK3CA E545G • PIK3CA E545X • PIK3CA G1049R • PIK3CA H1047X • PIK3CA Q546 • PIK3CA Q546K • PIK3CA Q546R
    |
    Aliqopa (copanlisib)
    over4years
    [VIRTUAL] Characteristics and clinical correlations of PI3K/AKT/mTOR pathway genetic variations in Chinese endometrial carcinoma (AACR-II 2020)
    Our study revealed gene variation characteristics of the PI3K/AKT/mTOR pathway in Chinese endometrial adenocarcinoma patients and the clinical correlations of these variations. PTEN mutations and truncation variations were associated with low grade phenotypes. This study was helpful for optimizing the usage of mTOR inhibitor everolimus.
    Clinical • Tumor Mutational Burden • MSi-H Biomarker
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • PTEN (Phosphatase and tensin homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1)
    |
    MSI-H/dMMR • PIK3CA mutation • PTEN deletion • PTEN mutation • FBXW7 mutation • PIK3R1 mutation • PIK3CA H1047X
    |
    everolimus